Axis MedTech will hold a number of interests that each represent a material opportunity to generate a return that is a multiple of the initial capitalisation
The Board of each subsidiary will have representation from Axis
Axis will have consent rights over budget and material changes thereto over subsidiaries
Subsidiaries will agree milestones prior to investment and will be required to deliver against these to access further funding, thereby minimising downside risk for investors
Maintaining each technology as separate entities maintains flexibility in value realisation, optimising the eventual outcome
Target return for each subsidiary will be 5x in five years
